Treatment of Eyes With Diabetic Macular Edema That Had a Suboptimal Response to Antivascular Endothelial Growth Factor Therapy: 2-mg Intravitreal Triamcinolone Acetonide vs 0.7-mg Dexamethasone Implant
Restricted accessResearch articleFirst published online October, 2020
Treatment of Eyes With Diabetic Macular Edema That Had a Suboptimal Response to Antivascular Endothelial Growth Factor Therapy: 2-mg Intravitreal Triamcinolone Acetonide vs 0.7-mg Dexamethasone Implant
This article compares 2-mg intravitreal triamcinolone (IVT) and 0.7-mg dexamethasone (DEX) implant for the treatment of diabetic macular edema in eyes that had a suboptimal response to antivascular endothelial growth factor therapy.
Methods:
A single-center, retrospective review was conducted of patients receiving either IVT between January 1, 2013, and January 1, 2018, or patients receiving DEX between October 1, 2015, and January 1, 2018. Visual acuity and central macular thickness (CMT) were recorded at visit of first injection and all subsequent visits.
Results:
Twenty-five eyes were included in the DEX group and 32 eyes were included in the IVT group. Change in vision from baseline was similar between DEX and IVT at 6-month follow-up (1.1 lines vs 2.3 lines, respectively; P = .24). Mean decrease in CMT from baseline was not different at 6-month follow-up (DEX: 120 µm vs IVT: 185 µm; P = .17).
Conclusions:
DEX and 2-mg IVT both achieved improvement in vision and CMT with no significant differences between treatment groups at 6-month follow-up.
CiullaTAAmadorAGZinmanB. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–2664. doi:10.2337/diacare.26.9.2653
2.
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1985;103(12):1796–1806. doi:10.1001/archopht.1985.01050120030015
3.
WangWLoACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):1816. doi:10.3390/ijms19061816
4.
Diabetic Retinopathy Clinical Research Network, ElmanMJAielloLP, et al.Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.e35. doi:10.1016/j.ophtha.2010.02.031
5.
CheungNWongIYWongTY. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care. 2014;37(4):900–905. doi:10.2337/dc13-1990
6.
BoyerDSYoonYHBelfortRJret al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
7.
Escobar-BarrancoJJPina-MarínBFernández-BonetM. Dexamethasone implants in patients with naive or refractory diffuse diabetic macular edema. Ophthalmologica. 2015;233(3-4):176–185. doi:10.1159/000371770
8.
IglickiMBuschCZurD, et al.Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the International Retina Group real-life 24-month multicenter study. The IRGREL-DEX study. Retina. 2019;39(1):44–51. doi:10.1097/IAE.0000000000002196
9.
PacellaFRomanoMRTurchettiP, et al.An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol. 2016;9(10):1427–1432. doi:10.18240/ijo.2016.10.10
10.
PacellaFFerraresiAFTurchettiP, et al.Intravitreal injection of Ozurdex((R)) implant in patients with persistent diabetic macular edema, with six-month follow-up. Ophthalmol Eye Dis. 2016;8:11–16. doi:10.4137/OED.S38028
11.
UnsalEEltutarKSultanPErkulSOOsmanbasogluOA. Efficacy and safety of intravitreal dexamethasone implants for treatment of refractory diabetic macular edema. Korean J Ophthalmol. 2017;31(2):115–122. doi: 10.3341/kjo.2017.31.2.115
12.
JeonSLeeWK. Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab. Retina. 2014;34(8):1606–1611. doi:10.1097/IAE.0000000000000109
13.
HallerJABandelloFBelfortRJr, et al.Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146.e3. doi:10.1016/j.ophtha.2010.03.032
14.
StoreyPPObeidAPancholyM, et al.Ocular hypertension after intravitreal injection of 2 mg triamcinolone. Retina. 2020;40(1):75–79. doi:10.1097/IAE.0000000000002361
15.
RegilloCDCallananDGDoDV, et al.Use of corticosteroids in the treatment of patients with diabetic macular edema who have a suboptimal response to anti-VEGF: recommendations of an expert panel. Ophthalmic Surg Lasers Imaging Retina. 2017;48(4):291–301. doi:10.3928/23258160-20170329-03
16.
BuschCZurDFraser-BellSet al; International Retina Group. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55(8):789–796. doi:10.1007/s00592-018-1151-x
17.
BresslerNMBeaulieuWTMaguireMGet al; Diabetic Retinopathy Clinical Research Network. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in Protocol T. Am J Ophthalmol. 2018;195:93–100. doi:S0002-9394(18)30413-6
18.
MaturiRKGlassmanARLiuDet al; Diabetic Retinopathy Clinical Research Network. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR Network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136(1):29–38. doi:10.1001/jamaophthalmol.2017.4914
19.
HauserDBukelmanAPokroyR, et al.Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg. Retina. 2008;28(6):825–830. doi:10.1097/IAE.0b013e318165767e
20.
Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447–1449.e10. doi:10.1016/j.ophtha.2008.06.015
